| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 100 | 2024 | 1502 | 12.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 32 | 2023 | 643 | 9.410 |
Why?
|
| Diet | 52 | 2023 | 801 | 8.220 |
Why?
|
| Mammography | 55 | 2024 | 188 | 7.950 |
Why?
|
| Breast | 32 | 2019 | 135 | 7.140 |
Why?
|
| Premenopause | 39 | 2021 | 104 | 6.440 |
Why?
|
| Soy Foods | 22 | 2016 | 60 | 6.420 |
Why?
|
| Adiposity | 17 | 2024 | 154 | 5.140 |
Why?
|
| Isoflavones | 27 | 2021 | 129 | 5.040 |
Why?
|
| Risk Factors | 99 | 2023 | 3562 | 4.330 |
Why?
|
| Cohort Studies | 63 | 2024 | 1492 | 4.310 |
Why?
|
| Aged | 117 | 2024 | 6741 | 4.190 |
Why?
|
| Middle Aged | 155 | 2024 | 10129 | 4.190 |
Why?
|
| Female | 213 | 2024 | 20969 | 4.110 |
Why?
|
| Obesity | 23 | 2023 | 1067 | 3.550 |
Why?
|
| Body Mass Index | 48 | 2024 | 854 | 3.380 |
Why?
|
| Hawaii | 75 | 2021 | 1929 | 3.360 |
Why?
|
| Mammary Glands, Human | 9 | 2018 | 39 | 3.350 |
Why?
|
| Humans | 227 | 2024 | 37093 | 3.320 |
Why?
|
| Lymphoma, Non-Hodgkin | 11 | 2023 | 39 | 3.320 |
Why?
|
| Estrogens | 11 | 2016 | 202 | 3.140 |
Why?
|
| Intra-Abdominal Fat | 8 | 2024 | 45 | 2.900 |
Why?
|
| Feeding Behavior | 15 | 2018 | 454 | 2.500 |
Why?
|
| Incidence | 32 | 2023 | 922 | 2.380 |
Why?
|
| Overweight | 8 | 2023 | 247 | 2.310 |
Why?
|
| Absorptiometry, Photon | 13 | 2023 | 75 | 2.230 |
Why?
|
| Case-Control Studies | 37 | 2024 | 1130 | 2.170 |
Why?
|
| Proportional Hazards Models | 30 | 2023 | 441 | 2.170 |
Why?
|
| Adult | 97 | 2023 | 11712 | 2.110 |
Why?
|
| Nipple Aspirate Fluid | 5 | 2013 | 14 | 2.070 |
Why?
|
| Male | 84 | 2024 | 20025 | 1.860 |
Why?
|
| Prospective Studies | 33 | 2023 | 1378 | 1.800 |
Why?
|
| Diet, Mediterranean | 5 | 2020 | 40 | 1.730 |
Why?
|
| Postmenopause | 18 | 2020 | 128 | 1.680 |
Why?
|
| Inflammation | 8 | 2022 | 618 | 1.670 |
Why?
|
| Colorectal Neoplasms | 8 | 2022 | 441 | 1.620 |
Why?
|
| Japan | 21 | 2019 | 305 | 1.540 |
Why?
|
| Cross-Sectional Studies | 32 | 2023 | 2721 | 1.360 |
Why?
|
| C-Reactive Protein | 10 | 2022 | 149 | 1.360 |
Why?
|
| Health Behavior | 7 | 2015 | 537 | 1.350 |
Why?
|
| Insulin-Like Growth Factor I | 7 | 2016 | 70 | 1.300 |
Why?
|
| California | 15 | 2019 | 476 | 1.300 |
Why?
|
| Leptin | 9 | 2018 | 118 | 1.270 |
Why?
|
| Soybean Proteins | 5 | 2014 | 38 | 1.240 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2024 | 481 | 1.160 |
Why?
|
| Subcutaneous Fat | 2 | 2023 | 15 | 1.150 |
Why?
|
| Sleep | 2 | 2019 | 152 | 1.130 |
Why?
|
| Follow-Up Studies | 19 | 2022 | 974 | 1.120 |
Why?
|
| Adiponectin | 6 | 2017 | 55 | 1.070 |
Why?
|
| Nutrition Assessment | 5 | 2018 | 79 | 1.030 |
Why?
|
| Body Fat Distribution | 3 | 2021 | 24 | 1.030 |
Why?
|
| Cross-Over Studies | 11 | 2021 | 108 | 1.000 |
Why?
|
| Gonadal Steroid Hormones | 4 | 2024 | 51 | 1.000 |
Why?
|
| Cacao | 2 | 2018 | 10 | 0.980 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 6 | 2010 | 23 | 0.960 |
Why?
|
| Parity | 4 | 2015 | 46 | 0.950 |
Why?
|
| Survivors | 4 | 2015 | 136 | 0.950 |
Why?
|
| Meat | 5 | 2013 | 43 | 0.930 |
Why?
|
| Muscles | 1 | 2023 | 82 | 0.920 |
Why?
|
| Body Composition | 6 | 2023 | 162 | 0.900 |
Why?
|
| Feces | 3 | 2021 | 111 | 0.880 |
Why?
|
| Micronutrients | 3 | 2019 | 44 | 0.880 |
Why?
|
| Body Weight | 5 | 2015 | 434 | 0.880 |
Why?
|
| Smoking | 13 | 2019 | 940 | 0.870 |
Why?
|
| Neoplasms | 11 | 2024 | 1103 | 0.870 |
Why?
|
| Nipples | 3 | 2013 | 14 | 0.830 |
Why?
|
| United States | 16 | 2023 | 4223 | 0.820 |
Why?
|
| Dietary Fiber | 3 | 2020 | 47 | 0.810 |
Why?
|
| Tocopherols | 3 | 2021 | 65 | 0.810 |
Why?
|
| Diabetes Mellitus | 7 | 2019 | 485 | 0.790 |
Why?
|
| Aged, 80 and over | 17 | 2022 | 2379 | 0.790 |
Why?
|
| Alcohol Drinking | 5 | 2015 | 519 | 0.780 |
Why?
|
| Chronic Disease | 2 | 2019 | 484 | 0.760 |
Why?
|
| Logistic Models | 12 | 2017 | 923 | 0.750 |
Why?
|
| Adolescent | 23 | 2023 | 5363 | 0.750 |
Why?
|
| Mortality | 2 | 2016 | 145 | 0.740 |
Why?
|
| Flavonoids | 2 | 2018 | 87 | 0.700 |
Why?
|
| Phytoestrogens | 4 | 2013 | 38 | 0.700 |
Why?
|
| Lipids | 3 | 2018 | 235 | 0.680 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2011 | 39 | 0.680 |
Why?
|
| Medicare | 5 | 2023 | 195 | 0.680 |
Why?
|
| Hydroxyestrones | 4 | 2017 | 8 | 0.670 |
Why?
|
| Thinness | 1 | 2019 | 29 | 0.670 |
Why?
|
| Estradiol | 6 | 2024 | 262 | 0.660 |
Why?
|
| Coffee | 2 | 2023 | 20 | 0.660 |
Why?
|
| Risk Assessment | 11 | 2020 | 753 | 0.660 |
Why?
|
| Vimentin | 1 | 2018 | 37 | 0.660 |
Why?
|
| Life Style | 7 | 2017 | 308 | 0.660 |
Why?
|
| Estrone | 4 | 2013 | 21 | 0.640 |
Why?
|
| Anticarcinogenic Agents | 2 | 2009 | 65 | 0.640 |
Why?
|
| Puberty | 2 | 2011 | 25 | 0.640 |
Why?
|
| Receptors, Progesterone | 4 | 2019 | 81 | 0.630 |
Why?
|
| Patient Compliance | 6 | 2012 | 212 | 0.620 |
Why?
|
| Los Angeles | 13 | 2021 | 380 | 0.620 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 98 | 0.620 |
Why?
|
| Oxidative Stress | 2 | 2015 | 938 | 0.610 |
Why?
|
| Meat Products | 1 | 2017 | 5 | 0.600 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 123 | 0.600 |
Why?
|
| Anthropometry | 5 | 2023 | 97 | 0.590 |
Why?
|
| Receptors, Estrogen | 3 | 2019 | 156 | 0.580 |
Why?
|
| Time Factors | 9 | 2019 | 1742 | 0.580 |
Why?
|
| Age Factors | 12 | 2015 | 1033 | 0.580 |
Why?
|
| Chromatography, Liquid | 3 | 2014 | 142 | 0.570 |
Why?
|
| Carotenoids | 5 | 2021 | 70 | 0.570 |
Why?
|
| Weight Gain | 2 | 2023 | 136 | 0.560 |
Why?
|
| Pilot Projects | 10 | 2019 | 661 | 0.560 |
Why?
|
| Sepsis | 1 | 2017 | 80 | 0.550 |
Why?
|
| Gene Expression | 2 | 2018 | 674 | 0.550 |
Why?
|
| Odds Ratio | 9 | 2019 | 534 | 0.520 |
Why?
|
| gamma-Tocopherol | 4 | 2019 | 19 | 0.520 |
Why?
|
| Antioxidants | 4 | 2015 | 416 | 0.510 |
Why?
|
| Phenotype | 8 | 2024 | 689 | 0.510 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 935 | 0.500 |
Why?
|
| Prognosis | 11 | 2019 | 739 | 0.490 |
Why?
|
| Plant Preparations | 2 | 2013 | 27 | 0.490 |
Why?
|
| Liver | 1 | 2017 | 479 | 0.480 |
Why?
|
| Stroke | 1 | 2018 | 286 | 0.480 |
Why?
|
| Adipokines | 1 | 2014 | 24 | 0.470 |
Why?
|
| Health Status Disparities | 3 | 2015 | 642 | 0.470 |
Why?
|
| Survival Rate | 7 | 2018 | 311 | 0.460 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2011 | 8 | 0.460 |
Why?
|
| Survival Analysis | 5 | 2020 | 325 | 0.460 |
Why?
|
| Epithelial Cells | 2 | 2013 | 384 | 0.450 |
Why?
|
| Mass Spectrometry | 2 | 2012 | 260 | 0.450 |
Why?
|
| Coffea | 1 | 2013 | 3 | 0.450 |
Why?
|
| Menstrual Cycle | 2 | 2004 | 35 | 0.450 |
Why?
|
| Tissue Array Analysis | 2 | 2013 | 67 | 0.440 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2024 | 767 | 0.440 |
Why?
|
| Attitude to Health | 3 | 2005 | 325 | 0.440 |
Why?
|
| Population Groups | 2 | 2022 | 56 | 0.440 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2009 | 121 | 0.430 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 20 | 0.430 |
Why?
|
| Isoprostanes | 1 | 2012 | 14 | 0.420 |
Why?
|
| Oncology Service, Hospital | 1 | 2012 | 1 | 0.420 |
Why?
|
| Vitamin D | 6 | 2023 | 196 | 0.410 |
Why?
|
| Phytotherapy | 1 | 2012 | 81 | 0.410 |
Why?
|
| Women's Health | 2 | 2011 | 145 | 0.410 |
Why?
|
| Reproductive History | 1 | 2012 | 19 | 0.410 |
Why?
|
| Child | 12 | 2023 | 3131 | 0.400 |
Why?
|
| RNA, Ribosomal, 16S | 4 | 2022 | 171 | 0.400 |
Why?
|
| Fatty Acids | 1 | 2012 | 127 | 0.400 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 935 | 0.390 |
Why?
|
| Eating | 4 | 2022 | 166 | 0.390 |
Why?
|
| Steroids | 1 | 2011 | 43 | 0.390 |
Why?
|
| Cytochrome P-450 CYP1A2 | 3 | 2007 | 28 | 0.380 |
Why?
|
| Blood Glucose | 2 | 2010 | 353 | 0.380 |
Why?
|
| Genome-Wide Association Study | 6 | 2024 | 333 | 0.380 |
Why?
|
| Vitamin D Deficiency | 4 | 2023 | 105 | 0.380 |
Why?
|
| Complementary Therapies | 6 | 2012 | 46 | 0.370 |
Why?
|
| Young Adult | 9 | 2023 | 4268 | 0.370 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2012 | 448 | 0.370 |
Why?
|
| Neoplasm Staging | 7 | 2011 | 275 | 0.370 |
Why?
|
| SEER Program | 6 | 2019 | 91 | 0.370 |
Why?
|
| Prevalence | 8 | 2012 | 1455 | 0.370 |
Why?
|
| Internship and Residency | 1 | 2012 | 125 | 0.370 |
Why?
|
| Motor Activity | 3 | 2015 | 418 | 0.360 |
Why?
|
| Linear Models | 6 | 2021 | 275 | 0.360 |
Why?
|
| Confidence Intervals | 5 | 2013 | 149 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2022 | 628 | 0.360 |
Why?
|
| Longitudinal Studies | 6 | 2019 | 885 | 0.360 |
Why?
|
| Menopause | 3 | 2007 | 56 | 0.350 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 893 | 0.350 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 400 | 0.350 |
Why?
|
| Plant Extracts | 1 | 2012 | 286 | 0.340 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2009 | 6 | 0.340 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 18 | 0.340 |
Why?
|
| Magnesium | 1 | 2009 | 97 | 0.340 |
Why?
|
| Waist Circumference | 2 | 2023 | 89 | 0.330 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2007 | 12 | 0.320 |
Why?
|
| Regression Analysis | 7 | 2015 | 455 | 0.320 |
Why?
|
| Risk | 5 | 2014 | 267 | 0.320 |
Why?
|
| Lymphoma, Follicular | 1 | 2008 | 2 | 0.320 |
Why?
|
| Hormones | 2 | 2013 | 55 | 0.310 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 19 | 0.310 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 15 | 0.310 |
Why?
|
| Lymphoma, T-Cell | 1 | 2008 | 28 | 0.310 |
Why?
|
| Lymphoma, B-Cell | 1 | 2008 | 23 | 0.310 |
Why?
|
| Comorbidity | 4 | 2018 | 623 | 0.310 |
Why?
|
| Sex Factors | 8 | 2013 | 898 | 0.300 |
Why?
|
| Prolactin | 1 | 2007 | 62 | 0.300 |
Why?
|
| Adipose Tissue | 5 | 2021 | 177 | 0.300 |
Why?
|
| Fruit | 5 | 2021 | 173 | 0.300 |
Why?
|
| Norway | 7 | 2016 | 9 | 0.290 |
Why?
|
| Diet Surveys | 6 | 2009 | 101 | 0.290 |
Why?
|
| Progesterone | 4 | 2012 | 113 | 0.280 |
Why?
|
| Vegetables | 4 | 2021 | 147 | 0.280 |
Why?
|
| Health Status Indicators | 1 | 2007 | 75 | 0.280 |
Why?
|
| Interleukin-6 | 3 | 2014 | 153 | 0.280 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 9 | 0.280 |
Why?
|
| Population Surveillance | 5 | 2012 | 238 | 0.270 |
Why?
|
| Obesity, Abdominal | 2 | 2019 | 30 | 0.270 |
Why?
|
| China | 4 | 2012 | 196 | 0.270 |
Why?
|
| Exercise | 3 | 2017 | 613 | 0.260 |
Why?
|
| Heptachlor | 1 | 2005 | 2 | 0.260 |
Why?
|
| Cause of Death | 2 | 2018 | 156 | 0.260 |
Why?
|
| Cholesterol, HDL | 2 | 2017 | 97 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2010 | 268 | 0.250 |
Why?
|
| Triglycerides | 2 | 2017 | 138 | 0.250 |
Why?
|
| Food Contamination | 1 | 2005 | 55 | 0.250 |
Why?
|
| Insecticides | 1 | 2005 | 51 | 0.240 |
Why?
|
| Family Health | 2 | 2017 | 56 | 0.240 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2024 | 12 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 356 | 0.240 |
Why?
|
| Sarcopenia | 1 | 2023 | 10 | 0.230 |
Why?
|
| Iceland | 2 | 2022 | 5 | 0.230 |
Why?
|
| Emigration and Immigration | 1 | 2004 | 82 | 0.230 |
Why?
|
| Sex Hormone-Binding Globulin | 4 | 2024 | 20 | 0.220 |
Why?
|
| Malnutrition | 1 | 2023 | 44 | 0.220 |
Why?
|
| Registries | 6 | 2019 | 335 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 63 | 0.210 |
Why?
|
| Testosterone | 3 | 2024 | 193 | 0.210 |
Why?
|
| Sex Distribution | 3 | 2011 | 215 | 0.210 |
Why?
|
| Mastectomy, Segmental | 1 | 2002 | 17 | 0.210 |
Why?
|
| Insurance Claim Review | 1 | 2002 | 28 | 0.200 |
Why?
|
| Cell Count | 2 | 2012 | 135 | 0.200 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2013 | 421 | 0.200 |
Why?
|
| Whole Body Imaging | 1 | 2021 | 25 | 0.200 |
Why?
|
| Body Height | 1 | 2022 | 53 | 0.200 |
Why?
|
| Health Surveys | 4 | 2012 | 373 | 0.200 |
Why?
|
| Vitamin A | 1 | 2021 | 87 | 0.190 |
Why?
|
| Databases, Factual | 1 | 2002 | 291 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2018 | 173 | 0.190 |
Why?
|
| Retrospective Studies | 5 | 2023 | 2026 | 0.190 |
Why?
|
| Genistein | 2 | 2013 | 42 | 0.190 |
Why?
|
| Pregnancy | 3 | 2022 | 1549 | 0.180 |
Why?
|
| Metformin | 1 | 2021 | 65 | 0.180 |
Why?
|
| Tamoxifen | 2 | 2018 | 65 | 0.180 |
Why?
|
| Prediabetic State | 1 | 2021 | 53 | 0.180 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 539 | 0.180 |
Why?
|
| Nutrition Surveys | 2 | 2014 | 242 | 0.180 |
Why?
|
| Glucose | 1 | 2021 | 230 | 0.170 |
Why?
|
| Calcifediol | 2 | 2023 | 15 | 0.170 |
Why?
|
| Diet, Reducing | 1 | 2019 | 24 | 0.170 |
Why?
|
| Multifactorial Inheritance | 1 | 2019 | 19 | 0.170 |
Why?
|
| Caloric Restriction | 1 | 2019 | 32 | 0.170 |
Why?
|
| Double-Blind Method | 3 | 2017 | 286 | 0.160 |
Why?
|
| Aging | 2 | 2017 | 664 | 0.160 |
Why?
|
| Arizona | 3 | 2007 | 100 | 0.160 |
Why?
|
| Flavanones | 1 | 2018 | 8 | 0.160 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 13 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 562 | 0.160 |
Why?
|
| Bacteria | 1 | 2021 | 255 | 0.160 |
Why?
|
| Perimenopause | 1 | 2017 | 4 | 0.150 |
Why?
|
| France | 1 | 2017 | 17 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 2 | 2016 | 111 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2008 | 208 | 0.150 |
Why?
|
| Singapore | 2 | 2010 | 14 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 111 | 0.150 |
Why?
|
| Dyslipidemias | 1 | 2017 | 43 | 0.140 |
Why?
|
| Energy Intake | 2 | 2015 | 170 | 0.140 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 225 | 0.140 |
Why?
|
| Soy Milk | 2 | 2008 | 6 | 0.140 |
Why?
|
| Body Image | 1 | 2017 | 84 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 18 | 0.140 |
Why?
|
| Indoles | 1 | 2017 | 158 | 0.130 |
Why?
|
| Diet Records | 2 | 2014 | 60 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 130 | 0.130 |
Why?
|
| F2-Isoprostanes | 1 | 2015 | 20 | 0.130 |
Why?
|
| Creatinine | 2 | 2014 | 103 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 182 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2017 | 184 | 0.130 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 62 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 191 | 0.130 |
Why?
|
| Kallikreins | 1 | 2014 | 9 | 0.120 |
Why?
|
| Food | 1 | 2015 | 100 | 0.120 |
Why?
|
| alpha-Tocopherol | 1 | 2014 | 27 | 0.120 |
Why?
|
| Ubiquinone | 1 | 2014 | 22 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2015 | 174 | 0.120 |
Why?
|
| Luteal Phase | 1 | 2013 | 5 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2014 | 88 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2016 | 305 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 229 | 0.120 |
Why?
|
| Cross-Cultural Comparison | 2 | 2004 | 107 | 0.120 |
Why?
|
| Hormone Replacement Therapy | 3 | 2015 | 41 | 0.110 |
Why?
|
| Educational Status | 3 | 2015 | 313 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 251 | 0.110 |
Why?
|
| Animals | 3 | 2023 | 15081 | 0.110 |
Why?
|
| Colonoscopy | 1 | 2014 | 104 | 0.110 |
Why?
|
| Adolescent Behavior | 2 | 2007 | 253 | 0.110 |
Why?
|
| Parturition | 1 | 2013 | 24 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 312 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 118 | 0.110 |
Why?
|
| Infant | 2 | 2008 | 1046 | 0.110 |
Why?
|
| Caffeine | 1 | 2013 | 28 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 664 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 48 | 0.110 |
Why?
|
| Minnesota | 1 | 2012 | 40 | 0.110 |
Why?
|
| Causality | 1 | 2012 | 44 | 0.110 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 34 | 0.100 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2009 | 43 | 0.100 |
Why?
|
| Korea | 1 | 2012 | 43 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2008 | 1418 | 0.100 |
Why?
|
| Philippines | 1 | 2012 | 73 | 0.100 |
Why?
|
| Mexican Americans | 1 | 2014 | 189 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 69 | 0.100 |
Why?
|
| Dietary Supplements | 2 | 2005 | 208 | 0.100 |
Why?
|
| Mass Screening | 2 | 2014 | 462 | 0.100 |
Why?
|
| Food Analysis | 1 | 2011 | 30 | 0.100 |
Why?
|
| Physician-Patient Relations | 2 | 2003 | 128 | 0.100 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 65 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2013 | 326 | 0.100 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 4 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2022 | 1369 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2011 | 59 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2011 | 18 | 0.100 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1067 | 0.100 |
Why?
|
| Cholesterol | 1 | 2012 | 205 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 29 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2010 | 4 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 4 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 113 | 0.090 |
Why?
|
| Ethanol | 1 | 2012 | 192 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2015 | 681 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 796 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2012 | 404 | 0.090 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 31 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1198 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 431 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 583 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1015 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 225 | 0.090 |
Why?
|
| Immune System Diseases | 1 | 2009 | 21 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 182 | 0.090 |
Why?
|
| Placebos | 1 | 2009 | 37 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1039 | 0.080 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2009 | 21 | 0.080 |
Why?
|
| Mothers | 1 | 2011 | 181 | 0.080 |
Why?
|
| Chemokine CCL4 | 1 | 2008 | 19 | 0.080 |
Why?
|
| Parathyroid Hormone | 1 | 2009 | 37 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 33 | 0.080 |
Why?
|
| Cytokines | 1 | 2013 | 602 | 0.080 |
Why?
|
| Quality of Life | 4 | 2012 | 481 | 0.080 |
Why?
|
| Genotype | 4 | 2015 | 730 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2008 | 28 | 0.080 |
Why?
|
| Bone Density | 1 | 2009 | 75 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 807 | 0.080 |
Why?
|
| Patient Satisfaction | 3 | 2005 | 145 | 0.080 |
Why?
|
| Fermentation | 1 | 2008 | 26 | 0.080 |
Why?
|
| Urinalysis | 2 | 2005 | 30 | 0.080 |
Why?
|
| Dairy Products | 2 | 2005 | 35 | 0.080 |
Why?
|
| Asia | 2 | 2006 | 75 | 0.080 |
Why?
|
| Research Design | 2 | 2007 | 313 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2009 | 230 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2010 | 387 | 0.080 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 85 | 0.080 |
Why?
|
| Specimen Handling | 1 | 2008 | 56 | 0.080 |
Why?
|
| Social Class | 1 | 2009 | 247 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 25 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 204 | 0.070 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 132 | 0.070 |
Why?
|
| Aspirin | 1 | 2007 | 49 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 213 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2007 | 550 | 0.070 |
Why?
|
| Androstenedione | 1 | 2006 | 17 | 0.070 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2006 | 27 | 0.070 |
Why?
|
| Social Identification | 1 | 2007 | 58 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 215 | 0.070 |
Why?
|
| Mental Recall | 2 | 2003 | 78 | 0.070 |
Why?
|
| Androgens | 1 | 2006 | 89 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2005 | 191 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 108 | 0.070 |
Why?
|
| Europe | 3 | 2011 | 101 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 97 | 0.060 |
Why?
|
| ROC Curve | 1 | 2005 | 138 | 0.060 |
Why?
|
| Pregnanediol | 1 | 2005 | 5 | 0.060 |
Why?
|
| Estriol | 1 | 2005 | 9 | 0.060 |
Why?
|
| Students | 2 | 2007 | 519 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2005 | 38 | 0.060 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2005 | 56 | 0.060 |
Why?
|
| Lymphoma | 1 | 2005 | 38 | 0.060 |
Why?
|
| Research | 1 | 2006 | 163 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2004 | 75 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 81 | 0.060 |
Why?
|
| Leukemia | 1 | 2005 | 56 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2005 | 84 | 0.060 |
Why?
|
| Self Concept | 1 | 2005 | 154 | 0.060 |
Why?
|
| Communication | 2 | 2003 | 180 | 0.060 |
Why?
|
| Insurance Claim Reporting | 1 | 2003 | 4 | 0.060 |
Why?
|
| Electric Impedance | 1 | 2023 | 25 | 0.060 |
Why?
|
| Information Services | 1 | 2003 | 14 | 0.060 |
Why?
|
| History, 17th Century | 1 | 2002 | 5 | 0.050 |
Why?
|
| Spirituality | 1 | 2003 | 49 | 0.050 |
Why?
|
| Dietary Fats | 3 | 2009 | 119 | 0.050 |
Why?
|
| Menarche | 1 | 2022 | 13 | 0.050 |
Why?
|
| Weight Loss | 1 | 2023 | 131 | 0.050 |
Why?
|
| Health Systems Plans | 1 | 2002 | 1 | 0.050 |
Why?
|
| Palpation | 1 | 2022 | 3 | 0.050 |
Why?
|
| Patients | 1 | 2002 | 14 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 14 | 0.050 |
Why?
|
| Growth | 1 | 2022 | 12 | 0.050 |
Why?
|
| Mice | 1 | 2013 | 5913 | 0.050 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2002 | 19 | 0.050 |
Why?
|
| Sunlight | 2 | 2014 | 47 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2002 | 63 | 0.050 |
Why?
|
| Smoking Cessation | 2 | 2007 | 517 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2022 | 27 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2002 | 43 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2005 | 894 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 97 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 81 | 0.050 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 205 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2005 | 864 | 0.050 |
Why?
|
| Medicaid | 1 | 2002 | 109 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 220 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 385 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 560 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 336 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2018 | 31 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2016 | 16 | 0.040 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2016 | 18 | 0.040 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 40 | 0.040 |
Why?
|
| International Agencies | 1 | 2015 | 6 | 0.030 |
Why?
|
| Algorithms | 1 | 2019 | 465 | 0.030 |
Why?
|
| Water | 1 | 2018 | 296 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 114 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 677 | 0.030 |
Why?
|
| Luciferases | 1 | 2015 | 63 | 0.030 |
Why?
|
| Schools | 2 | 2007 | 260 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 77 | 0.030 |
Why?
|
| Clostridium | 1 | 2014 | 21 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 188 | 0.030 |
Why?
|
| Actinobacteria | 1 | 2014 | 9 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 16 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 2014 | 34 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 12 | 0.030 |
Why?
|
| Uric Acid | 1 | 2014 | 26 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 997 | 0.030 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 14 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 22 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 47 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 972 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 68 | 0.020 |
Why?
|
| Beer | 1 | 2011 | 4 | 0.020 |
Why?
|
| Wine | 1 | 2011 | 9 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 31 | 0.020 |
Why?
|
| Carbonated Beverages | 1 | 2011 | 21 | 0.020 |
Why?
|
| Finland | 1 | 2010 | 13 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 30 | 0.020 |
Why?
|
| Beverages | 1 | 2011 | 68 | 0.020 |
Why?
|
| Seasons | 1 | 2010 | 112 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2009 | 6 | 0.020 |
Why?
|
| Health Promotion | 2 | 2007 | 653 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 321 | 0.020 |
Why?
|
| Milk | 1 | 2009 | 50 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 40 | 0.020 |
Why?
|
| Hyperparathyroidism | 1 | 2009 | 5 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 146 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 306 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2009 | 133 | 0.020 |
Why?
|
| Nicaragua | 1 | 2006 | 3 | 0.020 |
Why?
|
| New Zealand | 1 | 2006 | 21 | 0.020 |
Why?
|
| Africa | 1 | 2006 | 76 | 0.020 |
Why?
|
| Cultural Characteristics | 1 | 2007 | 125 | 0.020 |
Why?
|
| Australia | 1 | 2006 | 76 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2007 | 108 | 0.020 |
Why?
|
| School Health Services | 1 | 2007 | 81 | 0.020 |
Why?
|
| Peer Group | 1 | 2007 | 156 | 0.020 |
Why?
|
| Social Behavior | 1 | 2007 | 131 | 0.020 |
Why?
|
| Menstruation | 1 | 2005 | 10 | 0.020 |
Why?
|
| Narration | 1 | 2005 | 30 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 339 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2005 | 18 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 212 | 0.020 |
Why?
|
| Mastectomy | 1 | 2005 | 15 | 0.020 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2004 | 18 | 0.020 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2004 | 38 | 0.020 |
Why?
|
| Self Care | 1 | 2005 | 159 | 0.010 |
Why?
|
| Faith Healing | 1 | 2003 | 4 | 0.010 |
Why?
|
| Anecdotes as Topic | 1 | 2003 | 5 | 0.010 |
Why?
|
| Pacific Islands | 1 | 2003 | 119 | 0.010 |
Why?
|
| Professional Practice | 1 | 2002 | 4 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 61 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 2002 | 61 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 2002 | 64 | 0.010 |
Why?
|
| Culture | 1 | 2003 | 173 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 381 | 0.010 |
Why?
|
| Motivation | 1 | 2004 | 436 | 0.010 |
Why?
|
| Social Support | 1 | 2003 | 394 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 198 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 803 | 0.010 |
Why?
|